A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer (FAST-NL)

Ferring

Status: Completed

Conditions: Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01215526

FE200486 CS46

Details and patient eligibility

About

Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.

Enrollment: 274 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with advanced hormone-dependent prostate carcinoma that are eligible for hormone therapy

Exclusion criteria

• Patients with a contraindication for prescription of Firmagon®